Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 11/20 | 0.62 |
| ▸ | HTR3A | P46098 | 7/20 | 0.62 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.55 |
| ▸ | HTR3B | O95264 | 5/20 | 0.55 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.55 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6651774 | 0.91 | CHRNA7 (0.62) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6650684 | 0.87 | CHRNA7 (0.58) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL1965825 | 0.81 | CHRNA7 (0.74) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL261069 | 0.81 | CHRNA7 (0.61) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL15199691 | 0.81 | CHRNA7 (0.74) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6846164 | 0.81 | CHRNA7 (0.57) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6656459 | 0.81 | CHRNA7 (0.58) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6393701 | 0.81 | CHRNA7 (0.57) | CHRNA7 | |
| SCHEMBL6393705 | 0.81 | CHRNA7 (0.57) | CHRNA7 | |
| SCHEMBL6654598 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828330-B2 | Central nervous system disorders; schizophrenia; psychological disorders | PHARMACIA & UPJOHN COMPANY | 2004-12-07 | — | — | US | claimed |
| US-20040224977-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | WALKER DANIEL PATRICK (US) | 2004-11-11 | — | — | US | claimed |
| EP-1404674-A2 | QUINUCLIDINE-SUBSTITUTED HETEROAROMATIC COMPOUNDS AS LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-07 | — | — | EP | claimed |
| US-20030073707-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-17 | — | — | US | claimed |
| WO-2002100858-A2 | QUINUCLIDINE-SUBSTITUTED HETEROAROMATIC COMPOUNDS AS LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-19 | — | — | WO | claimed |
| US-6828330-B2 | Central nervous system disorders; schizophrenia; psychological disorders | PHARMACIA & UPJOHN COMPANY | 2004-12-07 | — | — | US | disclosed |
| US-20040224977-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | WALKER DANIEL PATRICK (US) | 2004-11-11 | — | — | US | disclosed |
| EP-1404674-A2 | QUINUCLIDINE-SUBSTITUTED HETEROAROMATIC COMPOUNDS AS LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030073707-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-17 | — | — | US | disclosed |
| WO-2002100858-A2 | QUINUCLIDINE-SUBSTITUTED HETEROAROMATIC COMPOUNDS AS LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073707-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | NAT1, UGT1A1, SLC10A1 | CHRNA7 672/4885HTR3A 1351/4885HTR3E 1837/4885 |
| US-20040224977-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | NAT1, UGT1A1, SLC10A1 | CHRNA7 672/4885HTR3A 1351/4885HTR3E 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.